Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

FlexWave-forsøg: Effekten af ​​ekstrakorporal chokbølgeterapi ved spasticitet efter slagtilfælde i øvre lemmer

15. november 2026 opdateret af: National Taiwan University Hospital

Effekter af ekstrakorporal chokbølge for øvre lemmer Flexor Spasticitet hos patienter med slagtilfælde: Et randomiseret kontrolleret forsøg

Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity.

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

This study aimed to evaluate the effects of focused Extracorporeal Shock Wave Therapy (ESWT) on upper limb flexor spasticity in stroke patients. Participants were randomized into two groups: an experimental group receiving targeted ESWT on specific forearm flexor muscles, and a control group receiving placebo treatments mimicking the shockwave therapy, with treatments administered twice weekly over two weeks for a total of four sessions.

The efficacy of the treatment was measured using a comprehensive set of assessment tools, including range of motion, hand grip strength, pain levels, spasticity scales, functional assessments, as well as measures of daily living activities, ultrasound strain elastography. The outcomes were evaluated at multiple points in time: before treatment, and 1, 4, 12, and 24 weeks after the therapy concluded, to assess both immediate and sustained effects of the treatment on upper limb function and spasticity in stroke survivors.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Taipei, Taiwan, 100
        • Department of Physical Medicine & Rehabilitation , National Taiwan University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Individuals aged 18 years or older with unilateral cerebral stroke.
  • Wrist/finger flexor muscle tone with a score greater than 1 on the Modified Ashworth Scale.
  • Stable medical condition and vital signs.
  • Conscious and able to comply with instructions.

Exclusion Criteria:

  • History of more than one stroke, traumatic brain injury, or cerebral neoplasm.
  • Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal diseases affecting muscle tone assessment.
  • Contraindications for shockwave intervention, such as malignancies, coagulopathies, local infections, or use of cardiac pacemakers.
  • Undergone shockwave therapy or botulinum toxin injections for post-stroke spasticity in the past three months.
  • Cognitive, consciousness, or language impairments preventing participation in the intervention or functional assessments.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Focused Extracorporeal Shock Wave Therapy

Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting three specific muscles: the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. Each muscle will receive 1,500 shockwave shots per session, accumulating to a total of 4,500 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions.

The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.

Placebo komparator: Placebo-Controlled Shockwave Therapy

Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves.

The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
modified Ashworth scale (MAS)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Evaluate spasticity in individuals with neurological conditions. The scale ranges from 0, indicating no increase in muscle tone, to 4, which represents severe spasticity with affected parts rigid in flexion or extension.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
modified Tardieu scale (MTS) R2-R1 Angle
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Difference between passive range of motion (R2) and the angle of muscle catch (R1), measured in degrees. Larger values indicate greater dynamic spasticity.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Tardieu grade
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Spasticity severity (0-5); higher grades indicate greater spasticity.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
passive range of motion for the wrist and finger joints
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

the extent to which a joint can be moved without the patient actively participating in the movement

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Medical Research Council (MRC) scale
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

grades voluntary muscle strength on a 0-5 ordinal scale

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
hand grip strength
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

use dynamometer to record the maximum force applied when the patient squeezes it

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Barthel index
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

measures a person's daily living abilities, focusing on ten areas of self-care and mobility. Scores range from 0 to 100, with higher scores denoting greater independence.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Functional Independence Measure (FIM)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

assesses a patient's level of disability and tracks changes over time, with a focus on physical and cognitive functioning across 18 items, scored from 18 (total assistance required) to 126 (fully independent).

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Wolf Motor Function Test (WMFT) Functional ability score
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

assess upper extremity function in individuals with neurological impairments, using 15 functional tasks. Scoring is on a 6-point ordinal scale, ranging from 0 ("Does not attempt with upper extremity being tested," indicating severe impairment) to 5 ("Movement appears to be normal," suggesting full functionality). Lower scores indicate greater impairment.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Action Research Arm Test (ARAT)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

a standardized measure evaluating upper limb motor ability in stroke patients, scoring from 0 (no movement) to 57 (normal arm function). It assesses grasp, grip, pinch, and gross arm movement.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Fugl-Meyer Assessment for the Upper Extremity (FMA-UE)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

range from 0 (complete paralysis) to 66 (full function), assessing motor recovery in post-stroke upper extremities

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
ultrasound assessment
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

used strain elastography to assess elasticity of forearm muscles

pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Shu-mei Yang, MD, National Taiwan University Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. april 2024

Primær færdiggørelse (Faktiske)

31. juli 2026

Studieafslutning (Faktiske)

31. juli 2026

Datoer for studieregistrering

Først indsendt

9. april 2024

Først indsendt, der opfyldte QC-kriterier

9. april 2024

Først opslået (Faktiske)

15. april 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. november 2026

Sidst verificeret

1. november 2025

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner